Supplies it“We produce spherical powders for AM processes, specifically engineered for the highest-demand, highest-value applications in defense, aerospace, space, medical devices, and industrial manufacturing.”
Sells it 84%, $8.5B a year“We offer a comprehensive suite of stapling, energy, and core instrumentation for our da Vinci surgical systems.”
Latest 10-KFY2025 ·
Intuitive Surgical delivered broad-based FY2025 growth as rising procedure volumes expanded recurring revenue and da Vinci 5 accelerated system placements. Revenue increased 21% and operating income increased 25%, despite lower gross margins from tariffs, new-system costs, manufacturing expansion, and service repairs. The investment case rests on converting a larger installed base into sustained…
da Vinci antitrust settlement drives a $450M charge and GAAP profit decline despite procedure and lease growth
Latest 8-KGovernance change ·
Bylaws tighten shareholder nomination and proxy rules; non-director-election actions shift to majority of votes cast, excluding abstentions and broker non-votes.
Latest 8-KBuybackExecutive payShareholder vote ·
Board expands buyback authorization to $5.0B; stockholders extend the incentive plan and increase its share reserve.
Latest 8-KPositiveDeal completed ·
Acquisition of da Vinci and Ion distributors expands direct operations in Italy, Spain and Portugal.
Sells it 36%, $33.8B a year“The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopaedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a wide range of acute and elective procedures.”
Latest 10-KFY2025 ·
DARZALEX and CARVYKTI growth offset STELARA’s biosimilar-driven decline; a talc reserve reversal boosted earnings without lifting operating cash flow.
Sells it 100%, $9.7B a quarter“Product adoption and successful commercialization—including pulsed-field ablation, Hugo robotic-assisted surgery, TAVR, renal denervation, ECMO and integrated spine offerings—remain important growth drivers, alongside regulatory approvals and safe, effective use.”
Sells it 52%, $159.7M a quarter“Both segments primarily serve OEM customers; Automation Enabling Technologies serves industrial, robotics, life-sciences and medical-laser applications, while Medical Solutions supplies surgical, imaging/RFID and operating-room technologies.”
Latest 10-QQ3 FY2026Restructuring ·
Riverpoint expands surgical consumables, but acquisition charges, amortization and financing costs overwhelm gains from stronger automation.
Sells it 73%, $4.8B a quarter“Stryker also cited uncertainty about the operational and financial effects of the cybersecurity incident first reported March 11, 2026, as well as costs associated with EU medical-device compliance, recalls, and regulatory and legal matters.”
Supplies it“We currently ship neural processors and AI software for use in regulated healthcare devices, where continuous, ultra‑low‑power on‑device inference is required to meet strict power, latency, reliability, and privacy requirements.”
Supplies it, part of Industrial Solutions“We specialize in the design and manufacture of advanced surgical, imaging, and interventional device solutions.”
Latest 10-KFY2026Positive ·
AI data-center and grid demand made Industrial Solutions the largest operating-profit contributor, reducing reliance on automotive.
Revenue$19.9BYoY +15.2%
Net income$3.3BYoY +76.6%
Latest 10-QQ3 FY2026PositiveRestructuring ·
AI and grid demand lifted Industrial Solutions profitability, while automotive price erosion squeezed transportation margins.
Revenue$5.2BYoY +13.8%
Net income$748.0MYoY +17.2%
Latest 8-KLeadership change ·
Jennifer A. Johnson will succeed John S. Jenkins, Jr. as legal chief; Jenkins will stay as an advisor until retiring in March 2027.
Latest 8-KPositiveEarningsNew guidance ·
AI and energy infrastructure demand drives Industrial Solutions growth; record backlog supports ≈$5.35B Q1 FY2027 sales outlook
No companies have a recent 8-K matching these events.